Trump's Phased Tariff Plan for Generic Drugs: 0% to 200%
UPSC / SSC current affairs note · Economy
Why in news
US President Donald Trump announced a phased tariff plan for imported generic drugs, starting at 0% for two years, then rising to 100% in 2028 and 200% thereafter. This move aims to incentivize drugmakers to shift production to the US, impacting global pharmaceutical supply chains and India's generic drug exports.
Background
The US is a major market for generic drugs, with India being a leading supplier. Trump's tariff plan is part of his 'America First' trade policy to reduce reliance on foreign manufacturing, especially in critical sectors like pharmaceuticals.
Key facts
Trump announced the plan via Truth Social on [date not specified].
From August 1, 2026, generic drug imports face 0% tariff for two years.
Tariff rises to 100% for one year starting August 1, 2028.
Thereafter, tariff increases to 200%.
The plan applies to all generic drugs brought into the US.
Purpose: to encourage drugmakers to move production to the US.
India is a major exporter of generic drugs to the US.
The plan could disrupt global pharmaceutical supply chains.
Prelims pointers
- US President: Donald Trump
- Policy: Phased tariff on generic drugs
- Timeline: 0% from Aug 1, 2026 for 2 years; 100% for 1 year; then 200%
- Sector: Pharmaceuticals, generic drugs
- India's role: Major generic drug exporter to US
Mains angles
- Impact on India's pharmaceutical exports and trade relations with US
- Analysis of 'America First' trade policy and its implications for global supply chains
- Strategic options for India to mitigate tariff impact (e.g., diversification, investment in US)
- WTO compatibility of such phased tariff increases